Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2971008 | The Journal of Heart and Lung Transplantation | 2012 | 9 Pages |
Abstract
Although HeartMate II LVAD implantation significantly increases survival compared with conventional medical management, it does not provide good value for the money spent according to established thresholds of cost-effectiveness in the UK. HeartMate II is unlikely to become cost-effective unless the additional survival gained by its use raises and/or the device is given free of charge. Therefore, its implantation to transplant candidates lacks justification in terms of cost-effectiveness.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Santiago G. PhD, Nicola PhD, Nicola J. PhD,